NCT03166631View on ClinicalTrials.gov

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

PHASE1TerminatedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 8, 2017

Primary Completion Date

September 15, 2020

Study Completion Date

October 28, 2020

Conditions
NeoplasmsNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung
Interventions
DRUG

BI 891065

Part A, Part B

DRUG

BI 754091

Part B

Trial Locations (3)

34232

Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Research Institute, Nashville

53226

Froedtert and The Medical College of Wisconsin, Milwaukee

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread | Biotech Hunter | Biotech Hunter